Literature DB >> 33704722

Single-Cell Analysis of BRAFV600E and NRASQ61R Mutation Status in Melanoma Cell Lines as Method Generation for Circulating Melanoma Cells.

Joseph W Po1,2,3, Yafeng Ma4,5,6, Alison W S Luk4,7, David Lynch4,5,8, Bavanthi Balakrishnar9, Daniel Brungs4,5,10, Farhad Azimi9, Adam Cooper5,8,9, Erin Saricilar8,6,9,11, Vinay Murthy4,5,8,9, Paul de Souza4,8,6,9,12, Therese M Becker4,5,8,6.   

Abstract

Molecular testing of tumor biopsies allows for the identification of the key mutations driving a patient's cancer. However, this is limited to singular nodes and may not accurately reflect cancer heterogeneity. Circulating tumor cell (CTC) analyses offer a noninvasive method of interrogating the genomic profile of patient-derived tumor material. To date, molecular analysis of CTCs has relied on the characterization of bulk or pooled CTC lysates, limiting the detection of minor tumorigenic CTC subclones. Here, we show a workflow enabling BRAFV600E/NRASQ61R mutation detection from single cultured melanoma cells by combining micromanipulation and genomic material amplification methods. This workflow can be directly integrated into circulating tumor cell analysis applications.

Entities:  

Keywords:  Cell lines; Circulating tumor cells (CTC); Liquid biopsy; Melanoma; Whole-genome amplification (WGA)

Mesh:

Substances:

Year:  2021        PMID: 33704722     DOI: 10.1007/978-1-0716-1205-7_21

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  24 in total

Review 1.  Implementing Genome-Driven Oncology.

Authors:  David M Hyman; Barry S Taylor; José Baselga
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 2.  Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.

Authors:  Young Kwang Chae; Alan P Pan; Andrew A Davis; Sandip P Patel; Benedito A Carneiro; Razelle Kurzrock; Francis J Giles
Journal:  Mol Cancer Ther       Date:  2017-12       Impact factor: 6.261

Review 3.  Precision Oncology: The Road Ahead.

Authors:  Daniela Senft; Mark D M Leiserson; Eytan Ruppin; Ze'ev A Ronai
Journal:  Trends Mol Med       Date:  2017-09-05       Impact factor: 11.951

4.  The biology and clinical potential of circulating tumor cells.

Authors:  Taja Lozar; Klara Gersak; Maja Cemazar; Cvetka Grasic Kuhar; Tanja Jesenko
Journal:  Radiol Oncol       Date:  2019-05-08       Impact factor: 2.991

Review 5.  Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers.

Authors:  Ruth Nussinov; Hyunbum Jang; Chung-Jung Tsai; Feixiong Cheng
Journal:  PLoS Comput Biol       Date:  2019-03-28       Impact factor: 4.475

Review 6.  Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity.

Authors:  Marta Tellez-Gabriel; Marie-Françoise Heymann; Dominique Heymann
Journal:  Theranostics       Date:  2019-06-19       Impact factor: 11.556

7.  Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors.

Authors:  Menno Tamminga; Sanne de Wit; T Jeroen N Hiltermann; Wim Timens; Ed Schuuring; Leon W M M Terstappen; Harry J M Groen
Journal:  J Immunother Cancer       Date:  2019-07-10       Impact factor: 13.751

8.  High Number of Circulating Tumor Cells Predicts Poor Survival of Cutaneous Melanoma Patients in China.

Authors:  Jisen Li; Wenhua Fu; Wei Zhang; Peng Li
Journal:  Med Sci Monit       Date:  2018-01-16

Review 9.  A conduit to metastasis: circulating tumor cell biology.

Authors:  Douglas S Micalizzi; Shyamala Maheswaran; Daniel A Haber
Journal:  Genes Dev       Date:  2017-09-15       Impact factor: 11.361

Review 10.  Tracking cancer progression: from circulating tumor cells to metastasis.

Authors:  Francesc Castro-Giner; Nicola Aceto
Journal:  Genome Med       Date:  2020-03-19       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.